SCHEMBL3457181

SCHEMBL3457181

CCOC(=O)Cc1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.70
GAA P10253 1/20 0.70
KMT2A Q03164 6/20 0.62
MEN1 O00255 4/20 0.62
KDM4E B2RXH2 1/20 0.62
SMN1; SMN2 Q16637 2/20 0.58
L3MBTL1 Q9Y468 3/20 0.56
PTGS2 P35354 1/20 0.53
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPK1 P28482 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NR4A1 P22736 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7131019 0.84 KMT2A (0.58) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL3227905 0.83 ALDH1A1 (0.52) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL491077 0.83 ALDH1A1 (0.62) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL908271 0.81 ABL1 (0.59) ALDH1A1GAAKMT2AMEN1SMN1; SMN2
SCHEMBL8111987 0.81 ALDH1A1 (0.50) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL11709705 0.81 ALDH1A1 (0.50) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL1008089 0.80 ALDH1A1 (0.49) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL31594790 0.80 ALDH1A1 (0.49) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL24296561 0.80 L3MBTL1 (0.63) ALDH1A1GAAKMT2AMEN1SMN1; SMN2
SCHEMBL9522214 0.80 MEN1 (0.58) ALDH1A1GAAKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104649879-B Substituted benzene methylene 1,2,3,4-Tetrahydrooxonaphthalene analog derivative and preparation method, application 中国人民解放军第二军医大学 2017-01-04 CN claimed
CN-104649879-A Substituted benzylidene tetralone derivatives and preparation method and applications UNIV PLA 2ND MILITARY MEDICAL 2015-05-27 CN claimed
CN-104649879-B Substituted benzene methylene 1,2,3,4-Tetrahydrooxonaphthalene analog derivative and preparation method, application 中国人民解放军第二军医大学 2017-01-04 CN disclosed
CN-104649879-A Substituted benzylidene tetralone derivatives and preparation method and applications UNIV PLA 2ND MILITARY MEDICAL 2015-05-27 CN disclosed
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2013-01-31 US disclosed
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2013-01-31 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
EP-2253333-A2 Contrast Agents for Myocardial Perfusion Imaging Lantheus Medical Imaging, Inc. (US) 2010-11-24 EP disclosed
CN-101896492-A Tetriacyclodipyranyl coumarins and the anti-HIV and anti-tuberculosis uses thereof INST OF MATARIA MEDICA CHINESE 2010-11-24 CN disclosed
US-7485283-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING (US) 2009-02-03 US disclosed
US-7485283-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING (US) 2009-02-03 US disclosed
EP-1740225-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING Bristol-Myers Squibb Company (US) 2007-01-10 EP disclosed
WO-2005105159-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-10 WO disclosed
US-20050244332-A1 Contrast agents for myocardial perfusion imaging CITIZENS BANK, N.A. 2005-11-03 US disclosed
CN-1176644-A Lewis X derivative and process for producing the same SUMITOMO PHARMA (JP) 1998-03-18 CN disclosed
EP-0801071-A1 LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-10-15 EP disclosed
US-4279918-A ANTIDEPRESSANTS, STIMULANTS BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) 1981-07-21 US disclosed
US-4221788-A 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1980-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050244332-A1 Contrast agents for myocardial perfusion imaging TNNI3, TNNT2, FABP3 ALDH1A1 2228/4885GAA 3445/4885KMT2A 4432/4885
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 ALDH1A1 2228/4885GAA 3445/4885KMT2A 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.